Bristol Myers Squibb (CELG-RI) Prepaid Assets (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Prepaid Assets of $4.6 billion for Q1 2026, down 16.93% year-over-year from $5.5 billion in Q1 2025, and little changed quarter-over-quarter from $4.6 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Prepaid Assets (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Prepaid Assets data on file, last reported at $4.6 billion in Q1 2026.
- Prepaid Assets for Q1 2026 came in at $4.6 billion, down 16.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 billion (down 16.93% YoY), and the FY2025 annual result was $4.6 billion, down 17.87% from the prior year.
- Prepaid Assets held at $4.6 billion in Q1 2026 per CELG-RI's latest filing, from $4.6 billion in the prior quarter.
- Over five years, Prepaid Assets peaked at $7.2 billion in Q3 2023 and troughed at $4.5 billion in Q1 2022.
- A 5-year average of $5.6 billion and a median of $5.6 billion in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2024: Prepaid Assets soared 39.11% in 2022, then fell 21.98% in 2024.
- A 5-year view of Prepaid Assets shows it stood at $5.8 billion in 2022, then increased by 1.93% to $5.9 billion in 2023, then retreated by 4.91% to $5.6 billion in 2024, then slipped by 17.87% to $4.6 billion in 2025, then dropped by 0.35% to $4.6 billion in 2026.
- Business Quant data shows CELG-RI's Prepaid Assets at $4.6 billion in Q1 2026, $4.6 billion in Q4 2025, and $4.9 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.60 Bn |
| Dec 31, 2025 | 4.61 Bn |
| Sep 30, 2025 | 4.95 Bn |
| Jun 30, 2025 | 5.47 Bn |
| Mar 31, 2025 | 5.53 Bn |
| Dec 31, 2024 | 5.62 Bn |
| Sep 30, 2024 | 5.62 Bn |
| Jun 30, 2024 | 5.74 Bn |
| Mar 31, 2024 | 5.57 Bn |
| Dec 31, 2023 | 5.91 Bn |
| Sep 30, 2023 | 7.21 Bn |
| Jun 30, 2023 | 6.87 Bn |
| Mar 31, 2023 | 5.16 Bn |
| Dec 31, 2022 | 5.80 Bn |
| Sep 30, 2022 | 6.08 Bn |
| Jun 30, 2022 | 5.76 Bn |
| Mar 31, 2022 | 4.54 Bn |
| Dec 31, 2021 | 4.83 Bn |
| Sep 30, 2021 | 4.37 Bn |
| Jun 30, 2021 | 5.04 Bn |